Production of Reactive Oxygen Species by Multipotent Stromal Cells/Mesenchymal Stem Cells upon Exposure to Fas Ligand

• Published in: Cell transplantation Vol. 21; no. 10; pp. 2171 - 2187
• Main Authors: Rodrigues, Melanie, Turner, Omari, Stolz, Donna, Griffith, Linda G., Wells, Alan
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.01.2012; SAGE Publishing
• Subjects: Apoptosis - drug effects; Apoptosis - physiology; Cell Culture Techniques; Fas Ligand Protein - pharmacology; Humans; Membrane Potential, Mitochondrial - drug effects; Membrane Potential, Mitochondrial - physiology; Mesenchymal Stromal Cells - drug effects; Mesenchymal Stromal Cells - metabolism; Oxidative Stress - drug effects; Oxidative Stress - physiology; p38 Mitogen-Activated Protein Kinases - genetics; p38 Mitogen-Activated Protein Kinases - metabolism; Reactive Oxygen Species - metabolism; Recombinant Proteins - pharmacology; Signal Transduction; Superoxides - metabolism; Marrow stromal cells; Reactive oxygen species (ROS); Multipotent stromal cells; Multipotent stem cells; Mesenchymal stem cells
• ISSN: 0963-6897; 1555-3892
• DOI: 10.3727/096368912X639035

Multipotent stromal cells (MSCs) can be differentiated into osteoblasts and chondrocytes, making these cells candidates to regenerate cranio-facial injuries and lesions in long bones. A major problem with cell replacement therapy, however, is the loss of transplanted MSCs at the site of graft. Reactive oxygen species (ROS) and nonspecific inflammation generated at the ischemic site have been hypothesized to lead to MSCs loss; studies in vitro show MSCs dying both in the presence of ROS or cytokines like FasL. We questioned whether MSCs themselves may be the source of these death inducers, specifically whether MSCs produce ROS under cytokine challenge. On treating MSCs with FasL, we observed increased ROS production within 2 h, leading to apoptotic death after 6 h of exposure to the cytokine. N-acetyl cysteine, an antioxidant, is able to protect MSCs from FasL-induced ROS production and subsequent ROS-dependent apoptosis, though the MSCs eventually succumb to ROS-independent death signaling. Epidermal growth factor (EGF), a cell survival factor, is able to protect cells from FasL-induced ROS production initially; however, the protective effect wanes with continued FasL exposure. In parallel, FasL induces upregulation of the uncoupling protein UCP2, the main uncoupling protein in MSCs, which is not abrogated by EGF; however, the production of ROS is followed by a delayed apoptotic cell death despite moderation by UCP2. FasL-induced ROS activates the stress-induced MAPK pathways JNK and p38MAPK as well as ERK, along with the activation of Bad, a proapoptotic protein, and suppression of survivin, an antiapoptotic protein; the latter two key modulators of the mitochondrial death pathway. FasL by itself also activates its canonical extrinsic death pathway noted by a time-dependent degradation of c-FLIP and activation of caspase 8. These data suggest that MSCs participate in their own demise due to nonspecific inflammation, holding implications for replacement therapies.